GSK plc’s strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating.
Hunter Brown and Framber Valdez were the constants in a season defined by injuries, Now, free agency awaits Valdez.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback